These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 33583086)

  • 1. Identification of tumors with NRG1 rearrangement, including a novel putative pathogenic UNC5D-NRG1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
    Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
    Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD74-NRG1 fusions in lung adenocarcinoma.
    Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
    Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
    Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
    J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multidriver mutation analysis in pulmonary mucinous adenocarcinoma in Taiwan: identification of a rare CD74-NRG1 translocation case.
    Gow CH; Wu SG; Chang YL; Shih JY
    Med Oncol; 2014 Jul; 31(7):34. PubMed ID: 24913807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
    Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
    J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VAMP2-NRG1 Fusion Gene is a Novel Oncogenic Driver of Non-Small-Cell Lung Adenocarcinoma.
    Jung Y; Yong S; Kim P; Lee HY; Jung Y; Keum J; Lee S; Kim J; Kim J
    J Thorac Oncol; 2015 Jul; 10(7):1107-11. PubMed ID: 26134228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful targeting of the NRG1 pathway indicates novel treatment strategy for metastatic cancer.
    Jones MR; Lim H; Shen Y; Pleasance E; Ch'ng C; Reisle C; Leelakumari S; Zhao C; Yip S; Ho J; Zhong E; Ng T; Ionescu D; Schaeffer DF; Mungall AJ; Mungall KL; Zhao Y; Moore RA; Ma Y; Chia S; Ho C; Renouf DJ; Gelmon K; Jones SJM; Marra MA; Laskin J
    Ann Oncol; 2017 Dec; 28(12):3092-3097. PubMed ID: 28950338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
    Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
    Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NRG1 fusion in a French cohort of invasive mucinous lung adenocarcinoma.
    Duruisseaux M; McLeer-Florin A; Antoine M; Alavizadeh S; Poulot V; Lacave R; Rabbe N; Cadranel J; Wislez M
    Cancer Med; 2016 Dec; 5(12):3579-3585. PubMed ID: 27770508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic Potential of Afatinib in NRG1 Fusion-Driven Solid Tumors: A Case Series.
    Cadranel J; Liu SV; Duruisseaux M; Branden E; Goto Y; Weinberg BA; Heining C; Schlenk RF; Cheema P; Jones MR; Drilon A; Trombetta D; Muscarella LA; Tolba K; Gounant V; Cseh A; Solca F; Laskin JJ; Renouf DJ
    Oncologist; 2021 Jan; 26(1):7-16. PubMed ID: 32852072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
    Laskin J; Liu SV; Tolba K; Heining C; Schlenk RF; Cheema P; Cadranel J; Jones MR; Drilon A; Cseh A; Gyorffy S; Solca F; Duruisseaux M
    Ann Oncol; 2020 Dec; 31(12):1693-1703. PubMed ID: 32916265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations.
    Chen YF; Hsieh MS; Wu SG; Chang YL; Shih JY; Liu YN; Tsai MF; Tsai TH; Yu CJ; Yang JC; Yang PC
    J Thorac Oncol; 2014 Aug; 9(8):1171-9. PubMed ID: 25157770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization.
    Werr L; Plenker D; Dammert MA; Lorenz C; Brägelmann J; Tumbrink HL; Klein S; Schmitt A; Büttner R; Persigehl T; Shokat KM; Wunderlich FT; Schram AM; Peifer M; Sos ML; Reinhardt HC; Thomas RK
    Mol Cancer Ther; 2022 May; 21(5):821-830. PubMed ID: 35247925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathologic Features and Response to Therapy of
    Drilon A; Duruisseaux M; Han JY; Ito M; Falcon C; Yang SR; Murciano-Goroff YR; Chen H; Okada M; Molina MA; Wislez M; Brun P; Dupont C; Branden E; Rossi G; Schrock A; Ali S; Gounant V; Magne F; Blum TG; Schram AM; Monnet I; Shih JY; Sabari J; Pérol M; Zhu VW; Nagasaka M; Doebele R; Camidge DR; Arcila M; Ou SI; Moro-Sibilot D; Rosell R; Muscarella LA; Liu SV; Cadranel J
    J Clin Oncol; 2021 Sep; 39(25):2791-2802. PubMed ID: 34077268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Pathways: Targeting NRG1 Fusions in Lung Cancer.
    Fernandez-Cuesta L; Thomas RK
    Clin Cancer Res; 2015 May; 21(9):1989-94. PubMed ID: 25501131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to ERBB3-Directed Targeted Therapy in
    Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
    Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinicopathological Characteristics of NRG1 Fusion-Positive Solid Tumors in Korean Patients.
    Cha YJ; Lee C; Joo B; Kim KA; Lee CK; Shim HS
    Cancer Res Treat; 2023 Oct; 55(4):1087-1095. PubMed ID: 37321274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with neuregulin 1 (NRG1) rearranged cancer are suitable for the theranostic approach and targeted therapy.
    Ondič O; Ptáková N; Janovský V; Vančurová J; Hósová M; Michal M; Pešek M
    Klin Onkol; 2022; 35(4):271-275. PubMed ID: 35989083
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Jones MR; Williamson LM; Topham JT; Lee MKC; Goytain A; Ho J; Denroche RE; Jang G; Pleasance E; Shen Y; Karasinska JM; McGhie JP; Gill S; Lim HJ; Moore MJ; Wong HL; Ng T; Yip S; Zhang W; Sadeghi S; Reisle C; Mungall AJ; Mungall KL; Moore RA; Ma Y; Knox JJ; Gallinger S; Laskin J; Marra MA; Schaeffer DF; Jones SJM; Renouf DJ
    Clin Cancer Res; 2019 Aug; 25(15):4674-4681. PubMed ID: 31068372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of NRG1 Gene Fusions in Solid Tumors.
    Jonna S; Feldman RA; Swensen J; Gatalica Z; Korn WM; Borghaei H; Ma PC; Nieva JJ; Spira AI; Vanderwalde AM; Wozniak AJ; Kim ES; Liu SV
    Clin Cancer Res; 2019 Aug; 25(16):4966-4972. PubMed ID: 30988082
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.